dr sol j barer  teva pharmaceutical industries pharmaceutical industries ltd see tevas sites around the world americas canada curacao united states growth markets argentina australia belarus brazil chile china india israel kazakhstan mexico peru russia singapore south africa turkey ukraine uruguay uzbekistan japan  s korea japan south korea europe europe austria belgium bosnia  herzegovina bulgaria croatia czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania macedonia monaco netherlands norway poland portugal romania serbia slovakia slovenia spain sweden switzerland united kingdom see all see less want to find out more about tevas locations and phone numbers visit teva worldwide home page about corporate governance board of directors dr sol j barer board of directors go to parent most read who we are dr sol j barer chairman of the board share on facebookshare on linkedin  ✉   dr barer became chairman of the board of directors on february   after joining teva’s board of directors in january  dr barer is managing partner at sj barer consulting he also serves as an advisor to the israel biotech fund from  to  he served in top leadership roles at celgene corporation including as executive chairman from  to  chairman and ceo from  to  ceo from  to  president and chief operating officer from  to  and president from  to  prior to that he was a founder of the biotechnology group at the chemical company celanese corporation which was later spun off as celgene dr barer serves on the board of directors of contrafect as lead director he served on the board of aegerion pharmaceuticals from  to november  on the board of amicus therapeutics from  to february  and as chairman of the board of inspiremd from  to june  dr barer is chairman of the board of edge therapeutics and aevi genomics formerly medgenics dr barer received his phd in organic and physical chemistry from rutgers university and his bs in chemistry from brooklyn college of the city university of new york with his long career as a senior pharmaceutical executive and leadership roles in various biopharmaceutical companies dr barer provides broad and experienced knowledge of the global pharmaceutical business and industry as well as extensive scientific expertise you may also like related reading our philosophy related reading open day at teva poland related reading teva canada  totheworld participate in ugandan mission related reading chinese deputy minister visits teva at kfar saba israel sol j barer former executive chairman and chairman of executive committee celgene corporation timesjavascript is disabled market profiles login sign up login sign up   edit person sol j barer former executive chairman and chairman of executive committee at celgene corporation location summit nj add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop sol j barer former executive chairman and chairman of executive committee at celgene corporation location summit nj add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop dr barer spent most of his professional career with the celgene corporation one of the fastest growing and most profitable global biopharmaceutical companies with a market capitalization of  billion products in over  countries with revenues of  billion in  he was chairman of celgene from january  until june  executive chairman from june  until jan  and chairman and chief executive officer from may  until june  previously he was appointed president in  and chief operating officer in  before assuming the ceo position he also served as senior vice president science and technology and vice presidentgeneral manager chiral products from october  to october  and vice president technology from september  to october dr barer is presently a consultant to the corporation on strategic matters and rd dr barer joined the celanese research company in  and formed the biotechnology group that was subsequently spun out to form celgene dr barer serves as chairman of the board of contrafect chairman of the board of cerecor and chairman of the board of inspiremd and is on the board of directors of aegerion pharmaceuticals amicus therapeutics and edge therapeutics he also serves as chair of the board of trustees of bionj the new jersey biotechnology organization is on the board of trustees of rutgers – the state university of new jersey the board of trustees of the liberty science center and the board of trustees of the tourette syndrome association he also serves as an advisor to a number of biotechnologymedical companies in  he was chairman of the university of medicine and dentistry of new jersey governor’s advisory committeewhich recommended sweeping changes in the structure of new jersey’s medical schools and public research universities he previously served as a commissioner of the nj commission on science and technology  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags na topics of influence web site na careers achievements investments related people edit view all sol j barercareer  celgene corporation former executive chairman and chairman of executive committee cerecor board member nobex corporation board member competencies edit view all sol j barereducation  rutgers the state university of new jersey brooklyn college edit sol j barerachievements and recognitions add milestone no milestones has been recorded for sol j barer edit sol j barerlinks add link no links has been recorded for sol j barer sol j barerinvestmentsacquisitions no investments has been recorded for sol j barer sol j barerinvestments representing others no investment reps has been recorded for sol j barer sol j barerrelated people colleagues at celgene corporation mark j alles executive vice president jan view all sol j barerrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies celgene  wikipedia celgene from wikipedia the free encyclopedia jump to navigation search celgene corporation type public traded as nasdaq celg nasdaq component sp  component sp  component industry biotechnology founded  headquarters summit new jersey us key people robert j hugin executive chairman sol j barer founder mark alles ceo products thalomid revlimid abraxane pomalystimnovid otezla revenue us  billion  us  billion  operating income us  billion  us  billion  net income us  billion  us  billion  total assets us  billion  us  billion  total equity us  billion  us  billion  number of employees  december  website wwwcelgenecom celgene corporation is an american biotechnology company that discovers develops and commercializes medicines for cancer and inflammatory disorders it is incorporated in delaware and headquartered in summit new jersey the companys major product is revlimid lenalidomide in combination with dexamethasone for the treatment of multiple myeloma patients revlimid is also approved in the united states for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk myelodysplastic syndromes mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is sold through proprietary riskmanagement distribution programs to ensure safe and appropriate use of these pharmaceuticals vidaza is approved for the treatment of patients with mds celgene cellular therapeutics a subsidiary is a public cord blood bank contents  history  company origin and acquisition history  executive history  products  productrelated history  litigation  antitrust allegations  see also  references  external links historyedit in  celgene originally a unit of the celanese corporation was spun off as an independent company following the merger of celanese corporation with american hoechst corporation in august  celgene acquired signal pharmaceuticals inc a privately held company that searches for and develops pharmaceuticals that regulate diseaserelated genes signal pharmaceuticals inc now operates as celgene research san diego a wholly owned subsidiary of celgene corporation in december  celgene acquired anthrogenesis a privately held new jerseybased biotherapeutics company and cord blood banking business which is developing technology for the recovery of stem cells from placental tissues following the completion of fullterm successful pregnancies anthrogenesis now operates as celgene cellular therapeutics a wholly owned subsidiary of celgene in  celegene certified mckesson specialty a specialty pharmacy as one of a select group of revassistsm program contract pharmacies to launch lenalidomide trade name revlimid as a specialty drug lenalidomide requires special handling and is therefore only available through the revassist program a unique distribution network employing only certified contracted specialty pharmacies in march  celgene closed its  billion acquisition of pharmion corporation in december  celgene announced the acquisition of gloucester pharmaceuticals in  celgene looked to relocate its uk headquarters from riverside house in windsor to a new development stockley park uxbridge in june  celgene corporation and abraxis bioscience inc jointly announced the signing of a definitive merger agreement in which celgene has agreed to acquire abraxis bioscience in january  celgene and avila therapeutics inc a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing announced a definitive merger agreement under which celgene corporation will acquire avila therapeutics inc under the terms of the merger agreement celgene will acquire avila therapeutics inc for  million in cash plus up to  million for milestones contingent upon the development and regulatory approval of avl as well as up to  million in potential milestone payments contingent upon the development and approval of candidates generated from the avilomics platform citing a market capitalization of us billion and stock appreciation of  celgene was forbes magazines number  ranked drug company of  in  celgene and oncomed pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompassing demcizumab and five other biologics from onomeds pipeline also in  sutro biopharma entered into a strategic collaboration and option agreement with celgene corporation to discover and develop multispecific antibodies and antibody drug conjugates adcs this new agreement follows the december  collaboration between the two companies and focuses on the field of immunooncology while further broadening the sutro platform for discovery development and manufacture of bestinclass biotherapeutics in april  celgene announced it would commence a collaboration with astrazeneca worth  million studying their phase iii immunooncology drug candidate medi later in the same month celgene announced it would acquire quanticel for up to  million aimed at enhancing their cancer drug pipeline through quanticels epigenetic modifier targeting applications in june  celgene announced it had licensed lyceras rorgamma agonist portfolio for up to  million and continue to develop its phase i lead compound lyc for the treatment of inflammatory bowel disease the licensing opportunity gives celgene the option to acquire lycera in july  the company announced it would acquire receptos for  billion in a move to strengthen the companys inflammation and immunology areas news of the deal sent celgene shares up  in after hours trading in may  the company announced it would launch partnership with agios pharmaceuticals developing metabolic immunooncology therapies the deal could net more than  billion for agios in january  the company announced it would acquire delinia for  million increasing the companys autoimmune disease therapy offerings company origin and acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list celgene   delinia acq    receptos acq    quanticel acq    avila therapeutics inc acq    abraxis bioscience inc acq    gloucester pharmaceuticals acq    pharmion corporation acq    anthrogenesis acq    signal pharmaceuticals inc acq    celgene spun off from celanese in  executive historyedit in march  bob hugin the companys long serving ceo retired his position and took the role of executive chairman bob hugin was succeeded in the ceo role by mark alles at the same time jacqualyn fouse was named as the companys president and coo fouse had joined the company in  as the cfo effective june   dr fouse will purportedly step down and be succeeded by scott smith president of the companys global inflammation  immunology franchise who joined the company in  productsedit product portfolio brand name drug names indication date approved usa partner alkeran melphalan palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary  glaxosmithkline alkeran melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate  glaxosmithkline thalomid thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl and maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrences    thalomid thalidomide in combination with dexamethasone treatment of patients with newly diagnosed multiple myeloma  glaxosmithkline focalin dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children and adolescents  novartis focalin xr dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children adolescents and adults  novartis vidaza azacitidine treatment of patients with refractory anemia chronic myelomonocytic leukemia    revlimid lenalidomide transfusion dependent anemia due to low or intermediate risk myelodysplastic syndromes associated with a deletion  q cytogenetic abnormality with or without additional cytogenetic abnormalities    revlimid lenalidomide in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy    productrelated historyedit in july  celgene received approval from the fda to market thalamid for the acute treatment of the cutaneous manifestations of moderate to severe enl in april  celgene reached an agreement with novartis pharma ag to license dmph celgenes chirally pure version of ritalin the fda subsequently granted approval to market dmph or focalin in november  in december  celgene received approval from the fda to market revlimid for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities in may  celgene received approval for thalamid in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma in june  celgene received full marketing authorization for revlimid in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the european commission litigationedit antitrust allegationsedit in  dr reddy’s laboratories requested and celgene refused to provide a samples of celgenes anticancer drug thalomid® thalidomide dr reddys laboratories sought the material for bioequivalency studies required to bring its own generic version of thalidomide to market in response to the refusal dr reddys laboratories filed a citizens petition with the fda asking the agency to adopt procedures that would ensure generic applicants the right to buy sufficient samples to perform bioequivalence testing of drugs that were subject to rems distribution restrictions celgene denied that it had behaved anticompetitively arguing that the legislative history strongly suggested that congress considered and rejected a proposed guaranteed access procedure like the one proposed by dr reddy’s celgene further argued that requiring innovator companies to sell their products to potential generic competitors would violate its intellectual property rights and subject it to liability risks in the event that patients were harmed in dr reddys studies generic manufacturer lannett company initiated antitrust litigation that accused celgene of using its rems for thalomid® thalidomide to violate the antimonopolization provisions of the sherman act in early  the district court denied celgene’s motion to dismiss the case was set for trial beginning in february  but the parties settled before the trial began thereby postponing further judicial review of antitrust claims premised on alleged abuse of rems distribution restrictions see alsoedit biotech and pharmaceutical companies in the new york metropolitan area pharmaceutical industry in switzerland sutro biopharma companies portal referencesedit  a b c d e f g h i celgene corp de  annual report form k xbrl united states securities and exchange commission february     celgene corp de  q quarterly report form q xbrl united states securities and exchange commission april      form k celgene corporation united states securities and exchange commission   celgene selects mckesson specialty as a revassist program pharmacy vendor to launch revlimid mckesson specialty to provide dispensing reimbursement and clinical services prnewswire harahan la  february  retrieved  november    celgene to acquire gloucester pharmaceuticals dec    new head quarters for celgene  stockley park greets new tenant uk construction magazine  october   check date values in date help  celgene to acquire abraxis bioscience inc jun    pdf httpwwwavilatxcomnewsavilacelgenepdf  missing or empty title help  grading pharma in  forbes december     staff january   oncomed celgene in b cancer stem cell collaboration industry watch gen eng biotechnol news p    sutro biopharma and celgene corporation enter multiyear strategic collaboration and option to acquire agreement   gen  news highlightsastrazeneca inks b in immunooncology deals as q profit dips gen   gen  news highlightscelgene to acquire quanticel for uptom gen   celgene licenses lyceras immune modulators in uptom deal gen   celgene to acquire receptos for b gen   celgene agios launch b metabolic immunooncology alliance  gen news highlights  gen gen   httpwwwgenengnewscomgennewshighlightscelgenebuysdeliniaformtoacquiretregtherapyforautoimmunediseases  a b c d a year into job celgene president and coo said to retire genetic engineering  biotechnology news february   retrieved february     drugsfda fda approved drug products food and drug administration retrieved    botts llp baker life science update baker botts llp retrieved february    external linksedit official website business data for celgene google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlecelgeneoldid categories companies in the nasdaq indexcompanies listed on nasdaqpharmaceutical companies established in companies in the nasdaq biotechnology indexbiotechnology companies of the united statescompanies based in union county new jerseysummit new jersey establishments in new jerseypharmaceutical companies based in new jerseyorphan drug companieslife sciences industrybiotechnology companies established in hidden categories cs errors datespages with citations lacking titlespages with citations having bare urlspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutschفارسیfrançaisitalianoportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view celgene  wikipedia celgene from wikipedia the free encyclopedia jump to navigation search celgene corporation type public traded as nasdaq celg nasdaq component sp  component sp  component industry biotechnology founded  headquarters summit new jersey us key people robert j hugin executive chairman sol j barer founder mark alles ceo products thalomid revlimid abraxane pomalystimnovid otezla revenue us  billion  us  billion  operating income us  billion  us  billion  net income us  billion  us  billion  total assets us  billion  us  billion  total equity us  billion  us  billion  number of employees  december  website wwwcelgenecom celgene corporation is an american biotechnology company that discovers develops and commercializes medicines for cancer and inflammatory disorders it is incorporated in delaware and headquartered in summit new jersey the companys major product is revlimid lenalidomide in combination with dexamethasone for the treatment of multiple myeloma patients revlimid is also approved in the united states for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk myelodysplastic syndromes mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is sold through proprietary riskmanagement distribution programs to ensure safe and appropriate use of these pharmaceuticals vidaza is approved for the treatment of patients with mds celgene cellular therapeutics a subsidiary is a public cord blood bank contents  history  company origin and acquisition history  executive history  products  productrelated history  litigation  antitrust allegations  see also  references  external links historyedit in  celgene originally a unit of the celanese corporation was spun off as an independent company following the merger of celanese corporation with american hoechst corporation in august  celgene acquired signal pharmaceuticals inc a privately held company that searches for and develops pharmaceuticals that regulate diseaserelated genes signal pharmaceuticals inc now operates as celgene research san diego a wholly owned subsidiary of celgene corporation in december  celgene acquired anthrogenesis a privately held new jerseybased biotherapeutics company and cord blood banking business which is developing technology for the recovery of stem cells from placental tissues following the completion of fullterm successful pregnancies anthrogenesis now operates as celgene cellular therapeutics a wholly owned subsidiary of celgene in  celegene certified mckesson specialty a specialty pharmacy as one of a select group of revassistsm program contract pharmacies to launch lenalidomide trade name revlimid as a specialty drug lenalidomide requires special handling and is therefore only available through the revassist program a unique distribution network employing only certified contracted specialty pharmacies in march  celgene closed its  billion acquisition of pharmion corporation in december  celgene announced the acquisition of gloucester pharmaceuticals in  celgene looked to relocate its uk headquarters from riverside house in windsor to a new development stockley park uxbridge in june  celgene corporation and abraxis bioscience inc jointly announced the signing of a definitive merger agreement in which celgene has agreed to acquire abraxis bioscience in january  celgene and avila therapeutics inc a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing announced a definitive merger agreement under which celgene corporation will acquire avila therapeutics inc under the terms of the merger agreement celgene will acquire avila therapeutics inc for  million in cash plus up to  million for milestones contingent upon the development and regulatory approval of avl as well as up to  million in potential milestone payments contingent upon the development and approval of candidates generated from the avilomics platform citing a market capitalization of us billion and stock appreciation of  celgene was forbes magazines number  ranked drug company of  in  celgene and oncomed pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompassing demcizumab and five other biologics from onomeds pipeline also in  sutro biopharma entered into a strategic collaboration and option agreement with celgene corporation to discover and develop multispecific antibodies and antibody drug conjugates adcs this new agreement follows the december  collaboration between the two companies and focuses on the field of immunooncology while further broadening the sutro platform for discovery development and manufacture of bestinclass biotherapeutics in april  celgene announced it would commence a collaboration with astrazeneca worth  million studying their phase iii immunooncology drug candidate medi later in the same month celgene announced it would acquire quanticel for up to  million aimed at enhancing their cancer drug pipeline through quanticels epigenetic modifier targeting applications in june  celgene announced it had licensed lyceras rorgamma agonist portfolio for up to  million and continue to develop its phase i lead compound lyc for the treatment of inflammatory bowel disease the licensing opportunity gives celgene the option to acquire lycera in july  the company announced it would acquire receptos for  billion in a move to strengthen the companys inflammation and immunology areas news of the deal sent celgene shares up  in after hours trading in may  the company announced it would launch partnership with agios pharmaceuticals developing metabolic immunooncology therapies the deal could net more than  billion for agios in january  the company announced it would acquire delinia for  million increasing the companys autoimmune disease therapy offerings company origin and acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list celgene   delinia acq    receptos acq    quanticel acq    avila therapeutics inc acq    abraxis bioscience inc acq    gloucester pharmaceuticals acq    pharmion corporation acq    anthrogenesis acq    signal pharmaceuticals inc acq    celgene spun off from celanese in  executive historyedit in march  bob hugin the companys long serving ceo retired his position and took the role of executive chairman bob hugin was succeeded in the ceo role by mark alles at the same time jacqualyn fouse was named as the companys president and coo fouse had joined the company in  as the cfo effective june   dr fouse will purportedly step down and be succeeded by scott smith president of the companys global inflammation  immunology franchise who joined the company in  productsedit product portfolio brand name drug names indication date approved usa partner alkeran melphalan palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary  glaxosmithkline alkeran melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate  glaxosmithkline thalomid thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl and maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrences    thalomid thalidomide in combination with dexamethasone treatment of patients with newly diagnosed multiple myeloma  glaxosmithkline focalin dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children and adolescents  novartis focalin xr dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children adolescents and adults  novartis vidaza azacitidine treatment of patients with refractory anemia chronic myelomonocytic leukemia    revlimid lenalidomide transfusion dependent anemia due to low or intermediate risk myelodysplastic syndromes associated with a deletion  q cytogenetic abnormality with or without additional cytogenetic abnormalities    revlimid lenalidomide in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy    productrelated historyedit in july  celgene received approval from the fda to market thalamid for the acute treatment of the cutaneous manifestations of moderate to severe enl in april  celgene reached an agreement with novartis pharma ag to license dmph celgenes chirally pure version of ritalin the fda subsequently granted approval to market dmph or focalin in november  in december  celgene received approval from the fda to market revlimid for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities in may  celgene received approval for thalamid in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma in june  celgene received full marketing authorization for revlimid in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the european commission litigationedit antitrust allegationsedit in  dr reddy’s laboratories requested and celgene refused to provide a samples of celgenes anticancer drug thalomid® thalidomide dr reddys laboratories sought the material for bioequivalency studies required to bring its own generic version of thalidomide to market in response to the refusal dr reddys laboratories filed a citizens petition with the fda asking the agency to adopt procedures that would ensure generic applicants the right to buy sufficient samples to perform bioequivalence testing of drugs that were subject to rems distribution restrictions celgene denied that it had behaved anticompetitively arguing that the legislative history strongly suggested that congress considered and rejected a proposed guaranteed access procedure like the one proposed by dr reddy’s celgene further argued that requiring innovator companies to sell their products to potential generic competitors would violate its intellectual property rights and subject it to liability risks in the event that patients were harmed in dr reddys studies generic manufacturer lannett company initiated antitrust litigation that accused celgene of using its rems for thalomid® thalidomide to violate the antimonopolization provisions of the sherman act in early  the district court denied celgene’s motion to dismiss the case was set for trial beginning in february  but the parties settled before the trial began thereby postponing further judicial review of antitrust claims premised on alleged abuse of rems distribution restrictions see alsoedit biotech and pharmaceutical companies in the new york metropolitan area pharmaceutical industry in switzerland sutro biopharma companies portal referencesedit  a b c d e f g h i celgene corp de  annual report form k xbrl united states securities and exchange commission february     celgene corp de  q quarterly report form q xbrl united states securities and exchange commission april      form k celgene corporation united states securities and exchange commission   celgene selects mckesson specialty as a revassist program pharmacy vendor to launch revlimid mckesson specialty to provide dispensing reimbursement and clinical services prnewswire harahan la  february  retrieved  november    celgene to acquire gloucester pharmaceuticals dec    new head quarters for celgene  stockley park greets new tenant uk construction magazine  october   check date values in date help  celgene to acquire abraxis bioscience inc jun    pdf httpwwwavilatxcomnewsavilacelgenepdf  missing or empty title help  grading pharma in  forbes december     staff january   oncomed celgene in b cancer stem cell collaboration industry watch gen eng biotechnol news p    sutro biopharma and celgene corporation enter multiyear strategic collaboration and option to acquire agreement   gen  news highlightsastrazeneca inks b in immunooncology deals as q profit dips gen   gen  news highlightscelgene to acquire quanticel for uptom gen   celgene licenses lyceras immune modulators in uptom deal gen   celgene to acquire receptos for b gen   celgene agios launch b metabolic immunooncology alliance  gen news highlights  gen gen   httpwwwgenengnewscomgennewshighlightscelgenebuysdeliniaformtoacquiretregtherapyforautoimmunediseases  a b c d a year into job celgene president and coo said to retire genetic engineering  biotechnology news february   retrieved february     drugsfda fda approved drug products food and drug administration retrieved    botts llp baker life science update baker botts llp retrieved february    external linksedit official website business data for celgene google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlecelgeneoldid categories companies in the nasdaq indexcompanies listed on nasdaqpharmaceutical companies established in companies in the nasdaq biotechnology indexbiotechnology companies of the united statescompanies based in union county new jerseysummit new jersey establishments in new jerseypharmaceutical companies based in new jerseyorphan drug companieslife sciences industrybiotechnology companies established in hidden categories cs errors datespages with citations lacking titlespages with citations having bare urlspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutschفارسیfrançaisitalianoportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view celgene  wikipedia celgene from wikipedia the free encyclopedia jump to navigation search celgene corporation type public traded as nasdaq celg nasdaq component sp  component sp  component industry biotechnology founded  headquarters summit new jersey us key people robert j hugin executive chairman sol j barer founder mark alles ceo products thalomid revlimid abraxane pomalystimnovid otezla revenue us  billion  us  billion  operating income us  billion  us  billion  net income us  billion  us  billion  total assets us  billion  us  billion  total equity us  billion  us  billion  number of employees  december  website wwwcelgenecom celgene corporation is an american biotechnology company that discovers develops and commercializes medicines for cancer and inflammatory disorders it is incorporated in delaware and headquartered in summit new jersey the companys major product is revlimid lenalidomide in combination with dexamethasone for the treatment of multiple myeloma patients revlimid is also approved in the united states for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk myelodysplastic syndromes mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is sold through proprietary riskmanagement distribution programs to ensure safe and appropriate use of these pharmaceuticals vidaza is approved for the treatment of patients with mds celgene cellular therapeutics a subsidiary is a public cord blood bank contents  history  company origin and acquisition history  executive history  products  productrelated history  litigation  antitrust allegations  see also  references  external links historyedit in  celgene originally a unit of the celanese corporation was spun off as an independent company following the merger of celanese corporation with american hoechst corporation in august  celgene acquired signal pharmaceuticals inc a privately held company that searches for and develops pharmaceuticals that regulate diseaserelated genes signal pharmaceuticals inc now operates as celgene research san diego a wholly owned subsidiary of celgene corporation in december  celgene acquired anthrogenesis a privately held new jerseybased biotherapeutics company and cord blood banking business which is developing technology for the recovery of stem cells from placental tissues following the completion of fullterm successful pregnancies anthrogenesis now operates as celgene cellular therapeutics a wholly owned subsidiary of celgene in  celegene certified mckesson specialty a specialty pharmacy as one of a select group of revassistsm program contract pharmacies to launch lenalidomide trade name revlimid as a specialty drug lenalidomide requires special handling and is therefore only available through the revassist program a unique distribution network employing only certified contracted specialty pharmacies in march  celgene closed its  billion acquisition of pharmion corporation in december  celgene announced the acquisition of gloucester pharmaceuticals in  celgene looked to relocate its uk headquarters from riverside house in windsor to a new development stockley park uxbridge in june  celgene corporation and abraxis bioscience inc jointly announced the signing of a definitive merger agreement in which celgene has agreed to acquire abraxis bioscience in january  celgene and avila therapeutics inc a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing announced a definitive merger agreement under which celgene corporation will acquire avila therapeutics inc under the terms of the merger agreement celgene will acquire avila therapeutics inc for  million in cash plus up to  million for milestones contingent upon the development and regulatory approval of avl as well as up to  million in potential milestone payments contingent upon the development and approval of candidates generated from the avilomics platform citing a market capitalization of us billion and stock appreciation of  celgene was forbes magazines number  ranked drug company of  in  celgene and oncomed pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompassing demcizumab and five other biologics from onomeds pipeline also in  sutro biopharma entered into a strategic collaboration and option agreement with celgene corporation to discover and develop multispecific antibodies and antibody drug conjugates adcs this new agreement follows the december  collaboration between the two companies and focuses on the field of immunooncology while further broadening the sutro platform for discovery development and manufacture of bestinclass biotherapeutics in april  celgene announced it would commence a collaboration with astrazeneca worth  million studying their phase iii immunooncology drug candidate medi later in the same month celgene announced it would acquire quanticel for up to  million aimed at enhancing their cancer drug pipeline through quanticels epigenetic modifier targeting applications in june  celgene announced it had licensed lyceras rorgamma agonist portfolio for up to  million and continue to develop its phase i lead compound lyc for the treatment of inflammatory bowel disease the licensing opportunity gives celgene the option to acquire lycera in july  the company announced it would acquire receptos for  billion in a move to strengthen the companys inflammation and immunology areas news of the deal sent celgene shares up  in after hours trading in may  the company announced it would launch partnership with agios pharmaceuticals developing metabolic immunooncology therapies the deal could net more than  billion for agios in january  the company announced it would acquire delinia for  million increasing the companys autoimmune disease therapy offerings company origin and acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list celgene   delinia acq    receptos acq    quanticel acq    avila therapeutics inc acq    abraxis bioscience inc acq    gloucester pharmaceuticals acq    pharmion corporation acq    anthrogenesis acq    signal pharmaceuticals inc acq    celgene spun off from celanese in  executive historyedit in march  bob hugin the companys long serving ceo retired his position and took the role of executive chairman bob hugin was succeeded in the ceo role by mark alles at the same time jacqualyn fouse was named as the companys president and coo fouse had joined the company in  as the cfo effective june   dr fouse will purportedly step down and be succeeded by scott smith president of the companys global inflammation  immunology franchise who joined the company in  productsedit product portfolio brand name drug names indication date approved usa partner alkeran melphalan palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary  glaxosmithkline alkeran melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate  glaxosmithkline thalomid thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl and maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrences    thalomid thalidomide in combination with dexamethasone treatment of patients with newly diagnosed multiple myeloma  glaxosmithkline focalin dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children and adolescents  novartis focalin xr dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children adolescents and adults  novartis vidaza azacitidine treatment of patients with refractory anemia chronic myelomonocytic leukemia    revlimid lenalidomide transfusion dependent anemia due to low or intermediate risk myelodysplastic syndromes associated with a deletion  q cytogenetic abnormality with or without additional cytogenetic abnormalities    revlimid lenalidomide in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy    productrelated historyedit in july  celgene received approval from the fda to market thalamid for the acute treatment of the cutaneous manifestations of moderate to severe enl in april  celgene reached an agreement with novartis pharma ag to license dmph celgenes chirally pure version of ritalin the fda subsequently granted approval to market dmph or focalin in november  in december  celgene received approval from the fda to market revlimid for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities in may  celgene received approval for thalamid in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma in june  celgene received full marketing authorization for revlimid in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the european commission litigationedit antitrust allegationsedit in  dr reddy’s laboratories requested and celgene refused to provide a samples of celgenes anticancer drug thalomid® thalidomide dr reddys laboratories sought the material for bioequivalency studies required to bring its own generic version of thalidomide to market in response to the refusal dr reddys laboratories filed a citizens petition with the fda asking the agency to adopt procedures that would ensure generic applicants the right to buy sufficient samples to perform bioequivalence testing of drugs that were subject to rems distribution restrictions celgene denied that it had behaved anticompetitively arguing that the legislative history strongly suggested that congress considered and rejected a proposed guaranteed access procedure like the one proposed by dr reddy’s celgene further argued that requiring innovator companies to sell their products to potential generic competitors would violate its intellectual property rights and subject it to liability risks in the event that patients were harmed in dr reddys studies generic manufacturer lannett company initiated antitrust litigation that accused celgene of using its rems for thalomid® thalidomide to violate the antimonopolization provisions of the sherman act in early  the district court denied celgene’s motion to dismiss the case was set for trial beginning in february  but the parties settled before the trial began thereby postponing further judicial review of antitrust claims premised on alleged abuse of rems distribution restrictions see alsoedit biotech and pharmaceutical companies in the new york metropolitan area pharmaceutical industry in switzerland sutro biopharma companies portal referencesedit  a b c d e f g h i celgene corp de  annual report form k xbrl united states securities and exchange commission february     celgene corp de  q quarterly report form q xbrl united states securities and exchange commission april      form k celgene corporation united states securities and exchange commission   celgene selects mckesson specialty as a revassist program pharmacy vendor to launch revlimid mckesson specialty to provide dispensing reimbursement and clinical services prnewswire harahan la  february  retrieved  november    celgene to acquire gloucester pharmaceuticals dec    new head quarters for celgene  stockley park greets new tenant uk construction magazine  october   check date values in date help  celgene to acquire abraxis bioscience inc jun    pdf httpwwwavilatxcomnewsavilacelgenepdf  missing or empty title help  grading pharma in  forbes december     staff january   oncomed celgene in b cancer stem cell collaboration industry watch gen eng biotechnol news p    sutro biopharma and celgene corporation enter multiyear strategic collaboration and option to acquire agreement   gen  news highlightsastrazeneca inks b in immunooncology deals as q profit dips gen   gen  news highlightscelgene to acquire quanticel for uptom gen   celgene licenses lyceras immune modulators in uptom deal gen   celgene to acquire receptos for b gen   celgene agios launch b metabolic immunooncology alliance  gen news highlights  gen gen   httpwwwgenengnewscomgennewshighlightscelgenebuysdeliniaformtoacquiretregtherapyforautoimmunediseases  a b c d a year into job celgene president and coo said to retire genetic engineering  biotechnology news february   retrieved february     drugsfda fda approved drug products food and drug administration retrieved    botts llp baker life science update baker botts llp retrieved february    external linksedit official website business data for celgene google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlecelgeneoldid categories companies in the nasdaq indexcompanies listed on nasdaqpharmaceutical companies established in companies in the nasdaq biotechnology indexbiotechnology companies of the united statescompanies based in union county new jerseysummit new jersey establishments in new jerseypharmaceutical companies based in new jerseyorphan drug companieslife sciences industrybiotechnology companies established in hidden categories cs errors datespages with citations lacking titlespages with citations having bare urlspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutschفارسیfrançaisitalianoportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view celgene  wikipedia celgene from wikipedia the free encyclopedia jump to navigation search celgene corporation type public traded as nasdaq celg nasdaq component sp  component sp  component industry biotechnology founded  headquarters summit new jersey us key people robert j hugin executive chairman sol j barer founder mark alles ceo products thalomid revlimid abraxane pomalystimnovid otezla revenue us  billion  us  billion  operating income us  billion  us  billion  net income us  billion  us  billion  total assets us  billion  us  billion  total equity us  billion  us  billion  number of employees  december  website wwwcelgenecom celgene corporation is an american biotechnology company that discovers develops and commercializes medicines for cancer and inflammatory disorders it is incorporated in delaware and headquartered in summit new jersey the companys major product is revlimid lenalidomide in combination with dexamethasone for the treatment of multiple myeloma patients revlimid is also approved in the united states for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk myelodysplastic syndromes mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is sold through proprietary riskmanagement distribution programs to ensure safe and appropriate use of these pharmaceuticals vidaza is approved for the treatment of patients with mds celgene cellular therapeutics a subsidiary is a public cord blood bank contents  history  company origin and acquisition history  executive history  products  productrelated history  litigation  antitrust allegations  see also  references  external links historyedit in  celgene originally a unit of the celanese corporation was spun off as an independent company following the merger of celanese corporation with american hoechst corporation in august  celgene acquired signal pharmaceuticals inc a privately held company that searches for and develops pharmaceuticals that regulate diseaserelated genes signal pharmaceuticals inc now operates as celgene research san diego a wholly owned subsidiary of celgene corporation in december  celgene acquired anthrogenesis a privately held new jerseybased biotherapeutics company and cord blood banking business which is developing technology for the recovery of stem cells from placental tissues following the completion of fullterm successful pregnancies anthrogenesis now operates as celgene cellular therapeutics a wholly owned subsidiary of celgene in  celegene certified mckesson specialty a specialty pharmacy as one of a select group of revassistsm program contract pharmacies to launch lenalidomide trade name revlimid as a specialty drug lenalidomide requires special handling and is therefore only available through the revassist program a unique distribution network employing only certified contracted specialty pharmacies in march  celgene closed its  billion acquisition of pharmion corporation in december  celgene announced the acquisition of gloucester pharmaceuticals in  celgene looked to relocate its uk headquarters from riverside house in windsor to a new development stockley park uxbridge in june  celgene corporation and abraxis bioscience inc jointly announced the signing of a definitive merger agreement in which celgene has agreed to acquire abraxis bioscience in january  celgene and avila therapeutics inc a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing announced a definitive merger agreement under which celgene corporation will acquire avila therapeutics inc under the terms of the merger agreement celgene will acquire avila therapeutics inc for  million in cash plus up to  million for milestones contingent upon the development and regulatory approval of avl as well as up to  million in potential milestone payments contingent upon the development and approval of candidates generated from the avilomics platform citing a market capitalization of us billion and stock appreciation of  celgene was forbes magazines number  ranked drug company of  in  celgene and oncomed pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompassing demcizumab and five other biologics from onomeds pipeline also in  sutro biopharma entered into a strategic collaboration and option agreement with celgene corporation to discover and develop multispecific antibodies and antibody drug conjugates adcs this new agreement follows the december  collaboration between the two companies and focuses on the field of immunooncology while further broadening the sutro platform for discovery development and manufacture of bestinclass biotherapeutics in april  celgene announced it would commence a collaboration with astrazeneca worth  million studying their phase iii immunooncology drug candidate medi later in the same month celgene announced it would acquire quanticel for up to  million aimed at enhancing their cancer drug pipeline through quanticels epigenetic modifier targeting applications in june  celgene announced it had licensed lyceras rorgamma agonist portfolio for up to  million and continue to develop its phase i lead compound lyc for the treatment of inflammatory bowel disease the licensing opportunity gives celgene the option to acquire lycera in july  the company announced it would acquire receptos for  billion in a move to strengthen the companys inflammation and immunology areas news of the deal sent celgene shares up  in after hours trading in may  the company announced it would launch partnership with agios pharmaceuticals developing metabolic immunooncology therapies the deal could net more than  billion for agios in january  the company announced it would acquire delinia for  million increasing the companys autoimmune disease therapy offerings company origin and acquisition historyedit the following is an illustration of the companys major mergers and acquisitions and historical predecessors this is not a comprehensive list celgene   delinia acq    receptos acq    quanticel acq    avila therapeutics inc acq    abraxis bioscience inc acq    gloucester pharmaceuticals acq    pharmion corporation acq    anthrogenesis acq    signal pharmaceuticals inc acq    celgene spun off from celanese in  executive historyedit in march  bob hugin the companys long serving ceo retired his position and took the role of executive chairman bob hugin was succeeded in the ceo role by mark alles at the same time jacqualyn fouse was named as the companys president and coo fouse had joined the company in  as the cfo effective june   dr fouse will purportedly step down and be succeeded by scott smith president of the companys global inflammation  immunology franchise who joined the company in  productsedit product portfolio brand name drug names indication date approved usa partner alkeran melphalan palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary  glaxosmithkline alkeran melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate  glaxosmithkline thalomid thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl and maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrences    thalomid thalidomide in combination with dexamethasone treatment of patients with newly diagnosed multiple myeloma  glaxosmithkline focalin dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children and adolescents  novartis focalin xr dexmethlyphenidate hydrochloride cii attention deficit hyperactivity disorder adhd in children adolescents and adults  novartis vidaza azacitidine treatment of patients with refractory anemia chronic myelomonocytic leukemia    revlimid lenalidomide transfusion dependent anemia due to low or intermediate risk myelodysplastic syndromes associated with a deletion  q cytogenetic abnormality with or without additional cytogenetic abnormalities    revlimid lenalidomide in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy    productrelated historyedit in july  celgene received approval from the fda to market thalamid for the acute treatment of the cutaneous manifestations of moderate to severe enl in april  celgene reached an agreement with novartis pharma ag to license dmph celgenes chirally pure version of ritalin the fda subsequently granted approval to market dmph or focalin in november  in december  celgene received approval from the fda to market revlimid for the treatment of patients with transfusiondependent anemia due to low or intermediaterisk mds associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities in may  celgene received approval for thalamid in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma in june  celgene received full marketing authorization for revlimid in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the european commission litigationedit antitrust allegationsedit in  dr reddy’s laboratories requested and celgene refused to provide a samples of celgenes anticancer drug thalomid® thalidomide dr reddys laboratories sought the material for bioequivalency studies required to bring its own generic version of thalidomide to market in response to the refusal dr reddys laboratories filed a citizens petition with the fda asking the agency to adopt procedures that would ensure generic applicants the right to buy sufficient samples to perform bioequivalence testing of drugs that were subject to rems distribution restrictions celgene denied that it had behaved anticompetitively arguing that the legislative history strongly suggested that congress considered and rejected a proposed guaranteed access procedure like the one proposed by dr reddy’s celgene further argued that requiring innovator companies to sell their products to potential generic competitors would violate its intellectual property rights and subject it to liability risks in the event that patients were harmed in dr reddys studies generic manufacturer lannett company initiated antitrust litigation that accused celgene of using its rems for thalomid® thalidomide to violate the antimonopolization provisions of the sherman act in early  the district court denied celgene’s motion to dismiss the case was set for trial beginning in february  but the parties settled before the trial began thereby postponing further judicial review of antitrust claims premised on alleged abuse of rems distribution restrictions see alsoedit biotech and pharmaceutical companies in the new york metropolitan area pharmaceutical industry in switzerland sutro biopharma companies portal referencesedit  a b c d e f g h i celgene corp de  annual report form k xbrl united states securities and exchange commission february     celgene corp de  q quarterly report form q xbrl united states securities and exchange commission april      form k celgene corporation united states securities and exchange commission   celgene selects mckesson specialty as a revassist program pharmacy vendor to launch revlimid mckesson specialty to provide dispensing reimbursement and clinical services prnewswire harahan la  february  retrieved  november    celgene to acquire gloucester pharmaceuticals dec    new head quarters for celgene  stockley park greets new tenant uk construction magazine  october   check date values in date help  celgene to acquire abraxis bioscience inc jun    pdf httpwwwavilatxcomnewsavilacelgenepdf  missing or empty title help  grading pharma in  forbes december     staff january   oncomed celgene in b cancer stem cell collaboration industry watch gen eng biotechnol news p    sutro biopharma and celgene corporation enter multiyear strategic collaboration and option to acquire agreement   gen  news highlightsastrazeneca inks b in immunooncology deals as q profit dips gen   gen  news highlightscelgene to acquire quanticel for uptom gen   celgene licenses lyceras immune modulators in uptom deal gen   celgene to acquire receptos for b gen   celgene agios launch b metabolic immunooncology alliance  gen news highlights  gen gen   httpwwwgenengnewscomgennewshighlightscelgenebuysdeliniaformtoacquiretregtherapyforautoimmunediseases  a b c d a year into job celgene president and coo said to retire genetic engineering  biotechnology news february   retrieved february     drugsfda fda approved drug products food and drug administration retrieved    botts llp baker life science update baker botts llp retrieved february    external linksedit official website business data for celgene google finance yahoo finance reuters sec filings v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlecelgeneoldid categories companies in the nasdaq indexcompanies listed on nasdaqpharmaceutical companies established in companies in the nasdaq biotechnology indexbiotechnology companies of the united statescompanies based in union county new jerseysummit new jersey establishments in new jerseypharmaceutical companies based in new jerseyorphan drug companieslife sciences industrybiotechnology companies established in hidden categories cs errors datespages with citations lacking titlespages with citations having bare urlspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutschفارسیfrançaisitalianoportuguêssuomi edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view  sol j barer  forbescom home business tech markets entrepreneurs leadership personal finance forbeslife lists opinions video blogs email newsletters portfolio tracker special reports commerce energy health care logistics manufacturing media services technology wall street washington cio network enterprise tech infoimaging internet infrastructure internet personal tech sciences security wireless bonds commodities currencies economy emerging markets equities options finance human resources law  taxation sales  marketing management technology careers compensation corporate citizenship corporate governance managing innovation ceo network reference etfs guru insights investing ideas investor education mutual funds philanthropy retirement  college taxes  estates collecting health real estate sports style travel vehicles wine  food  top celebrities  richest americans largest private cos worlds richest people all forbes lists business opinions investing technology opinions washington  the world companies people reference technology companies events people reference companies people companies events people reference companies events people reference ceo compensation  sol j barer   pm edt previous john c martinnext keith a hutton total compensation  mil year compensation total  mil sol j barer has been ceo of celgene celg for  years dr barer has been with the company for  years the  year old executive ranks  within drugs  biotechnology education college graduate school rutgers university phd          sol j barers compensation vs drugs  biotechnology medians salary  mil          mil  bonus  mil   mil  other  mil   mil  stock gains  mil   mil  total compensation mil  mil  celgene celg quote news  morris avenuesummit nj new jersey wwwcelgenecom sol j barers ownership of celgene industry medians stock owned  of co      stock owned   mil   mil    celgenes stock performance   total return during tenure    relative to market    previous john c martinnext keith a hutton rank  name  age  company  efficiency total compensation   year compensation  market value methodology compensation rank is based on total compensation for latest fiscal year total compensation for each chief executive includes the following salary and bonuses other compensation such as vested restricted stock grants ltip payouts and perks and stock gains the value realized by exercising stock options efficiency rank is based on our chief executives performancepay score ranks are given only to chief executives who have a sixyear tenure and sixyear compensation history the most efficient rank is  and least efficient is  footnotes compensation data is from the latest available proxy statements filed through april   total returns and value of stock owned including all classes is based on apr   stock price compensation percent change is based on combined salary and bonus annualized total return during tenure covers the tenure of the executive or from the time of the ipo or available stock history relative to market is the ending value of  invested in the stock divided by the ending value of  invested in the s  p  a score of   the s  p  na not available or not applicable annualized fouryear total threeyear total less than  prioryear data new chief executive compensation may be for another executive office less than  includes shares indirectly held return is for less than tenure sources company sec filings interactive data and lionshares via factset research systems salarycoms companalyst executive forbes beware of space junkamericas credit ratingacorn a democratic party albatrossheinekens new brew read all comments sol j barer phd joins inspiremd board of directors sol j barer phd joins inspiremd board of directors founder of celgene plus year biotechnology business leader becomes director jul    et from inspiremd telaviv israel july   prnewswire  inspiremd inc otc bb nspr inspire or the company the developer of the mguard™ mesh protective stent system announced today that sol j barer a biotechnology industry veteran and the founder and former chairman president coo and ceo of celgene a nasdaqlisted company nasdaq celg has joined the companys board of directors dr barer brings to inspiremd over  years of experience with publicly traded biotechnology companies in  when dr barer was with celanese research company he formed the biotechnology group that was subsequently spun out to form celgene dr barer spent  years leading celgene as president coo and ceo culminating with his tenure as celgenes executive chairman and chairman before retiring in june of  celgenes market capitalization at his retirement was approximately  billion dr barer is a director of amicus therapeutics inc aegerion pharmaceuticals inc and contrafect corp and serves as a senior advisor to a number of other biotechnology companies dr barer also serves as chairman of the board of trustees of the biotechnology council of new jersey and is on the board of trustees of rutgers university the brooklyn college foundation and the tourette syndrome association dr barer was previously the commissioner of the new jersey commission on science and technology dr barer holds a phd in organic chemistry from rutgers university and a bachelors degree from brooklyn college asher holzer cofounder and president of inspiremd commented it is an honor to add such an accomplished and recognized biotechnology leader like sol barer to our board of directors i am confident we will benefit from dr barers experience expertise and industry relationships as we pursue fda approval and build a firstrate sales and marketing organization dr barers years of developing and securing regulatory approval for lifesaving and transformational products coupled with his proven management and business expertise will be invaluable assets for inspiremd dr barer added i am looking forward to working with inspiremd to advance patient care in addressing a currently unmet need in the treatment of heart attack patients and ultimately save lives about mguard™ coronary mguard™ is a combination of a coronary stent merged with an embolic protection specifically designed for acute mi patients the embolic protection is comprised of an ultrathin polymer mesh sleeve that wraps the stent the mguard™ coronary seeks to provide permanent embolic protection without affecting deliverability mguard™ is ce mark approved meshbased protection is now recommended for use in the recent guidelines of the task force of myocardial revascularization of the european society of cardiology esc about inspiremd inc inspiremd is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology mguard™ inspiremd intends to pursue applications of this technology in coronary carotid and peripheral artery procedures inspiremds common stock is listed on the otc bb under the ticker symbol nspr forwardlooking statements this press release contains forwardlooking statements such statements may be preceded by the words intends may will plans expects anticipates projects predicts estimates aims believes hopes potential or similar words forwardlooking statements are not guarantees of future performance are based on certain assumptions and are subject to various known and unknown risks and uncertainties many of which are beyond the companys control and cannot be predicted or quantified and consequently actual results may differ materially from those expressed or implied by such forwardlooking statements such risks and uncertainties include without limitation risks and uncertainties associated with i market acceptance of our existing and new products ii negative clinical trial results or lengthy product delays in key markets iii an inability to secure regulatory approvals for the sale of our products iv intense competition in the medical device industry from much larger multinational companies v product liability claims vi our limited manufacturing capabilities and reliance on subcontractors for assistance vii insufficient or inadequate reimbursement by governmental and other third party payers for our products viii our efforts to successfully obtain and maintain intellectual property protection covering our products which may not be successful ix legislative or regulatory reform of the healthcare system in both the us and foreign jurisdictions x our reliance on single suppliers for certain product components xi the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly dilutive or difficult to obtain and xii the fact that we conduct business in multiple foreign jurisdictions exposing us to foreign currency exchange rate fluctuations logistical and communications challenges burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction more detailed information about the company and the risk factors that may affect the realization of forwardlooking statements is set forth in the companys filings with the securities and exchange commission including the companys registration statement on form s filed with the sec on june   investors and security holders are urged to read these documents free of charge on the secs web site at wwwsecgov the company assumes no obligation to publicly update or revise its forwardlooking statements as a result of new information future events or otherwise company contact wwwinspiremdcom jonina ohayon marketing director joninainspiremdcom otc bb nspr investor contact jeffrey stanlis partner hayden ir jeffhaydenircom   source inspiremd related links httpwwwinspiremdcom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jul    et preview inspiremd enrolls first patient in the master mguard for acute st elevation reperfusion randomized trial jun    et preview inspiremd broadens global distribution network signs distributor for the russian federation my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search immunomedics appoints dr sol j barer special advisor to the chairman nasdaqimmu english français register sign in immunomedics appoints dr sol j barer special advisor to the chairman april    et  source immunomedics morris plains nj april   globe newswire  immunomedics inc nasdaqimmu today announced that dr sol j barer has been appointed special advisor to the chairman and will work in this capacity to strengthen the company’s business and commercial development activities dr barer is managing partner of sj barer consulting from  to  he served in various senior management roles at celgene corporation including executive chairman chairman and ceo and president and coo prior thereto he was a founder of the biotechnology group at celanese corporation which then became celgene dr barer serves on the board of directors of teva pharmaceutical industries contrafect amicus therapeutics and aegerion pharmaceuticals in addition to four other healthcare companies he received a phd in organic and physical chemistry from rutgers university and a bs in chemistry from brooklyn college of the city of new york dr david m goldenberg chairman and founder of immunomedics commented “the board of directors and i are delighted and honored to have such a successful and seasoned biopharmaceutical executive join our team this is a pivotal time for the company as we advance our lead antibodydrug conjugate sacituzumab govitecan in partnering efforts towards eventual commercialization in the therapy of patients with triplenegative breast cancer as well as other major cancer types” “we look forward to dr barer playing an important role in the company’s developments” dr goldenberg added dr barer remarked “i have observed immunomedics for many years since celgene and immunomedics both were neighbors in warren nj i admire the diverse and innovative scientific platforms being developed and look forward to assisting in strategic development and commercialization of their novel antibodydrug conjugates as well as immunooncology products in early development” “it is critical to bring these and other compounds in development to the benefit of cancer patients as soon as possible” dr barer commented further about immunomedicsimmunomedics is a clinicalstage biopharmaceutical company developing monoclonal antibodybased products for the targeted treatment of cancer autoimmune disorders and other serious diseases immunomedics’ advanced proprietary technologies allow the company to create humanized antibodies that can be used either alone in unlabeled or “naked” form or conjugated with radioactive isotopes chemotherapeutics cytokines or toxins using these technologies immunomedics has built a pipeline of eight clinicalstage product candidates immunomedics’ portfolio of investigational products includes antibodydrug conjugates adcs that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents immunomedics’ most advanced adcs are sacituzumab govitecan immu and labetuzumab govitecan immu which are in phase  trials for a number of solid tumors and metastatic colorectal cancer respectively immu has received breakthrough therapy designation from fda for the treatment of patients with triplenegative breast cancer who have failed at least  prior therapies for metastatic disease immunomedics has a research collaboration with bayer to study epratuzumab as a thoriumlabeled antibody immunomedics has other ongoing collaborations in oncology with independent cancer study groups the intreall intereuropean study group is conducting a large randomized phase  trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in australia europe and israel immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies as well as other diseases in various stages of clinical and preclinical development these include combination therapies involving its antibodydrug conjugates bispecific antibodies targeting cancers and infectious diseases as tcell redirecting immunotherapies as well as bispecific antibodies for nextgeneration cancer and autoimmune disease therapies created using its patented dockandlock® protein conjugation technology the company believes that its portfolio of intellectual property which includes approximately  active patents in the united states and more than  foreign patents protects its product candidates and technologies for additional information on the company please visit its website at wwwimmunomedicscom the information on its website does not however form a part of this press release this release in addition to historical information may contain forwardlooking statements made pursuant to the private securities litigation reform act of  such statements including statements regarding clinical trials including the funding therefor outcomes timing or associated costs outlicensing arrangements including the timing and amount of contingent payments forecasts of future operating results potential collaborations and capital raising activities involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein factors that could cause such differences include but are not limited to new product development including clinical trials outcome and regulatory requirementsactions the company’s dependence on business collaborations in order to further develop our products and finance our operations the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates risks associated with the outcome of pending litigation and competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms if at all as well as the risks discussed in the company’s filings with the securities and exchange commission the company is not under any obligation and the company expressly disclaims any obligation to update or alter any forwardlooking statements whether as a result of new information future events or otherwisefor more information dr chau cheng senior director investor relations  corporate secretary   extension  cchengimmunomedicscom related articles other press releases by immunomedics published results from clinical trials demonstrate therapeutic potential for immunomedics’ sacituzumab govitecan immu in the treatment of metastatic solid cancers july    immunomedics announces results of special stockholder meeting june    immunomedics to present at jefferies  global healthcare conference june    immunomedics announces third quarter fiscal  results and clinical program developments may    immunomedics announces conference call and webcast for third quarter fiscal  results may     other news releases in directors and officers in the last  days profile immunomedics   subscribe via rss  subscribe via atom  javascript morris plains new jersey united states contact data for more information dr chau cheng senior director investor relations  corporate secretary   extension  cchengimmunomedicscom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved fold sol j barer insider trades for amicus therapeutics inc bulletin investor alert tokyo markets open in us market snapshot currencies commodities expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close amicus therapeutics inc nasdaq fold go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus amicus therapeutics inc after hours  quotes are delayed by  min jul    pm fold quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual sol j barer transactions date shares transaction value     acquisition at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr john francis crowley chairman  chief executive officer mr bradley l campbell president  chief operating officer mr william d baird chief financial officer dr jay a barth chief medical officer dr hung do chief scientific officer dr enrique dilone senior vice presidenttechnical operations ms daphne e quimi senior vice presidentfinance  administration mr dipal doshi chief business officer mr jeffrey p castelli svpprogram management  portfolio planning ms jayne c gershkowitz chief patient advocate dr kenneth j valenzano senior vice presidentpreclinical research mr patrik s florencio chief compliance officer mr willem w van weperen regional vice president mr david allsopp senior vice presidentinternational mr mark baldry vice presidentglobal marketing ms sara pellegrino headinvestor  media relations mr kurt j w andrews senior vice presidenthuman resources ms ellen stacy rosenberg secretary  general counsel dr andrew e mulberg vice presidentregulatory strategy mr john r kirk vice presidentregulatory affairs mr craig a wheeler independent director mr glenn p sblendorio independent director mr donald j hayden lead independent director mr robert a essner independent director dr ted w love independent director mr michael g raab independent director ms margaret g mcglynn independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pthis is what might be next for oj simpson after parole pweekend roundup companies that may cut dividends  faang stocks and market bubbles  enjoy london on the cheap pwhy you might want to avoid these  dividend stocks pattention shoppers ‘amazon effect’ is creating bargain stocks pas gdp will show us economy on same track pstocks brace for volatility in earnings deluge fed meeting looms adunkirk storms us box office with  million debut aoj simpson made over  while in prison and won’t have to give any of it to the goldman family aactor john heard ‘home alone’ dad dead at  amicrosoft rides huge tax benefit from failing at smartphones to big earnings beat aamazon’s foray into groceries means more mergers of food companies experts say ayogaworks ipo pulled on valuation concerns not market conditions aqualcomm’s issues go beyond apple fight apay tv expected to lose more than a million subscribers in latest quarter aexxon earnings will stock trade higher on expected secondquarter beat aalphabet earnings a  billion hit for google potential youtube results for investors achipotle earnings media coverage of the latest illness scare will put earnings targets at risk anolan’s cinematic vision in ‘dunkirk’ is hollywood’s best defense against netflix age earnings departing ceo immelt’s last chance to bring good things to investors abitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  sol j barer ph d joins inspire md board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       sol j barer phd joins inspire md board of directors tweet   am telaviv israel july   prnewswire  inspiremd inc otc bb nspr inspire or the company the developer of the mguard mesh protective stent system announced today that sol j barer a biotechnology industry veteran and the founder and former chairman president coo and ceo of celgene a nasdaqlisted company nasdaq celg has joined the companys board of directors dr barer brings to inspiremd over  years of experience with publicly traded biotechnology companies in  when dr barer was with celanese research company he formed the biotechnology group that was subsequently spun out to form celgene dr barer spent  years leading celgene as president coo and ceo culminating with his tenure as celgenes executive chairman and chairman before retiring in june of  celgenes market capitalization at his retirement was approximately  billion dr barer is a director of amicus therapeutics inc aegerion pharmaceuticals inc and contrafect corp and serves as a senior advisor to a number of other biotechnology companies dr barer also serves as chairman of the board of trustees of the biotechnology council of new jersey and is on the board of trustees of rutgers university the brooklyn college foundation and the tourette syndrome association dr barer was previously the commissioner of the new jersey commission on science and technology dr barer holds a phd in organic chemistry from rutgers university and a bachelors degree from brooklyn collegeasher holzer cofounder and president of inspiremd commented it is an honor to add such an accomplished and recognized biotechnology leader like sol barer to our board of directors i am confident we will benefit from dr barers experience expertise and industry relationships as we pursue fda approval and build a firstrate sales and marketing organization dr barers years of developing and securing regulatory approval for lifesaving and transformational products coupled with his proven management and business expertise will be invaluable assets for inspiremddr barer added i am looking forward to working with inspiremd to advance patient care in addressing a currently unmet need in the treatment of heart attack patients and ultimately save lives about mguard coronarymguard is a combination of a coronary stent merged with an embolic protection specifically designed for acute mi patients the embolic protection is comprised of an ultrathin polymer mesh sleeve that wraps the stent the mguard coronary seeks to provide permanent embolic protection without affecting deliverability mguard is ce mark approved meshbased protection is now recommended for use in the recent guidelines of the task force of myocardial revascularization of the european society of cardiology esc about inspiremd incinspiremd is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology mguard inspiremd intends to pursue applications of this technology in coronary carotid and peripheral artery procedures inspiremds common stock is listed on the otc bb under the ticker symbol nsprforwardlooking statements this press release contains forwardlooking statements such statements may be preceded by the words intends may will plans expects anticipates projects predicts estimates aims believes hopes potential or similar words forwardlooking statements are not guarantees of future performance are based on certain assumptions and are subject to various known and unknown risks and uncertainties many of which are beyond the companys control and cannot be predicted or quantified and consequently actual results may differ materially from those expressed or implied by such forwardlooking statements such risks and uncertainties include without limitation risks and uncertainties associated with i market acceptance of our existing and new products ii negative clinical trial results or lengthy product delays in key markets iii an inability to secure regulatory approvals for the sale of our products iv intense competition in the medical device industry from much larger multinational companies v product liability claims vi our limited manufacturing capabilities and reliance on subcontractors for assistance vii insufficient or inadequate reimbursement by governmental and other third party payers for our products viii our efforts to successfully obtain and maintain intellectual property protection covering our products which may not be successful ix legislative or regulatory reform of the healthcare system in both the us and foreign jurisdictions x our reliance on single suppliers for certain product components xi the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly dilutive or difficult to obtain and xii the fact that we conduct business in multiple foreign jurisdictions exposing us to foreign currency exchange rate fluctuations logistical and communications challenges burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction more detailed information about the company and the risk factors that may affect the realization of forwardlooking statements is set forth in the companys filings with the securities and exchange commission including the companys registration statement on form s filed with the sec on june   investors and security holders are urged to read these documents free of charge on the secs web site at wwwsecgov the company assumes no obligation to publicly update or revise its forwardlooking statements as a result of new information future events or otherwise company contactwwwinspiremdcomjonina ohayonmarketing directorjoninainspiremdcomotc bb nsprinvestor contactjeffrey stanlispartner hayden irjeffhaydenircom source inspiremd read at biospacecom related news inspire md demonstrates mguardtm stent system helps prevent distal embolization students develop computerized system to prevent sids bengurion university of the negev study inspire md increases geographic penetration mguard stent is now available in india new fdacleared sensititre aim automated inoculation delivery system from magellan biosciences inc provides faster accurate dosing of mic plates for microbiology laboratories inspire md announces yeartodate  progress apax partners cppib and psp in  billion deal for kinetic concepts inc kci inspire md promotes mguardtm at the europcr  exhibition and conference in paris this week heart ultrasound helps determine risk of heart attack death in hiv patients columbia university college of physicians and surgeons study kirloskar technologies ties up with israeli company inspire md to sell stents invasive diagnostic procedure for cystic fibrosis does not improve outcomes university of queensland study please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • inspire md   • diagnostics • medical dev  diag  personnel                 medgenicscom microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft loading your search results  peoplelookercom updating data on  please wait  seconds more okay address lookup  property search  beenverifiedcom public data for personal matters questions  login every address tells a story search millions of property values deeds owners transactions and more search property records search millions of property values deeds owners transactions and more see who owns a property search millions of property values deeds owners transactions and more search mortgage records search millions of property values deeds owners transactions and more search property deeds search millions of property values deeds owners transactions and more every address tells a story search property owners records and more who owns this property search millions of property values deeds owners transactions and more start here  try searching your home your neighbors or another address address   search know the name of a property owner find out about them here search by owners name property data can help you find a home you will have access to data about property values sales prices loans deed history nearby sex offenders and much more connect with owners unlike other property websites beenverified will help you connect with the owners of every address go beyond the address your first property search opens the door to billions of public records about people places phone numbers and online identities the intersection of data and the real world beenverified helps you incorporate property records and public data into your life         reports run by users  b i l l i o n  public data points billions of records at your fingertips with over  downloads so far beenverified is the goto choice for mobile public data access incredibly simple to use and useful this app has saved the day on finding so many addresses i needed definitely recommend”   via the app store always improving beenverified is relentless in its pursuit of providing you with better public data search an address reverse property reverse address lookup search millions of property values deeds owners transactions and more start here try searching your home your neighbors or another address search we respect your privacy what makes us different property data  people data our reports include the traditional info you’d expect to find about a property ownership deeds tax info etc but we dig deeper and offer background records on people too find criminal background records on owners registered sex offenders in the neighborhood and more the extras we include for free run criminal background checks on previous owners their associates or the neighbors get to know the whole story know your new neighborhood by seeing sex offender information which may include names addresses and criminal convictions easy to use reporting just enter an address a name or even a phone number and we will give you all the information we have “excellent support  service”  via sitejabbercom  supportbeenverifiedcom mon  fri  am   pm estsat  sun  am   pm est our goal is to provide helpful support that is quick and easy carla director of customer service about us about bv people search testimonials careers leadership press white pages criminal records our apps all bv apps for iphone  ipad  download for apple watch  download for android  download developer api help support contact us dos  donts faq remove my info affiliates glossary disclaimer beenverified’s mission is to give people easy and affordable access to public record information beenverified does not provide private investigator services and is not a consumer reporting agency as defined by the fair credit report act because the information provided by beenverified is not collected or provided in whole or in part for the purpose of furnishing consumer reports about those search subjects for more information governing the permitted and prohibited uses of beenverified please review our “do’s  don’ts” and our terms  conditions beenverified   all rights reserved terms  conditions privacy policy online background checks  beenverified × beenverifiedcom looking to find out about someone so have the  people who have tried beenverified start here  try searching a friend relative date neighbor or even yourself people phone email property we respect your privacy first name last name state all states alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming   search phone number   search email address   search street address   search we respect your privacy  reports  counting sol barer  wowcom  web results aol search skip over navigation search the web web images images reference reference we found sol barer  beenverifiedcom ad · wwwbeenverifiedcom  sol barers phone  address  age  social profiles people search search by name search by email best background check social media get contact information sol barers history  sol barers past available online ad · recordstruthfindercom sol barers past available online simply search a name and state search records now best background check find out the truth learn more best people search search arrest records searches related tosol barer sol barer net worth sol barer biography sol barer worth sol barer mendham nj dr sol j barer sj barer consulting celgene immediate past chair web results  sol j barer  forbescom httpswwwforbescomlistsbosssoljbarerlfshtml total compensation   mil year compensation total   mil sol j barer has been ceo of celgene for  years dr barer has been with the company for  years dr sol j barer  teva pharmaceutical industries wwwtevapharmcomboardofdirectorssoljbarer our board of directors includes dr sol j barer who serves as a director of teva pharmaceutical industries view his profile for more information sol j barer phd  executive bio compensation history  peopleequilarcombiosolbareramicustherapeuticssalary view sol j barer phd former chairman at inspiremd inc boston ma executive profile on equilar atlas to see current salary at inspiremd inc and compensation  edge therapeutics inc » sol barer phd wwwedgetherapeuticscomteamsolbarerphd sol barer phd dr sol barer has served on the edge therapeutics inc board of directors since september of  and is the current board chairman and chair of  sol barer elected chairman of israels teva pharmaceuticals wwwnjbizcomarticlenjbizsolbarerelected wellknown new jersey pharmaceutical industry executive dr sol barer has been elected chairman of the board of israeli pharma firm teva pharmaceutical industries … sol barer  professional profile httpswwwlinkedincominsolbarerbaa view sol barer’s professional profile on linkedin linkedin is the worlds largest business network helping professionals like sol barer discover inside  celgene cofounder sol barer bags a johns hopkins immuno  httpsendptscomcelgenecofoundersolbarerbagsajohns celgene cofounder sol barer bags a johns hopkins immunooncology spinout in buyout  barer joshua barer and  dr sol j barerphd  executive bio  compensation history executivesfindthecompanycomldrsoljbarerphd find compensation and employment information for dr sol j barerphd celgene including salary stock awards and previous employers sol barer  aevi genomic medicine inc insider transactions  httpswwwtiprankscominsiderssolbarer sol barer director at aevi genomic medicine inc gnmx has a  success rate when buying and selling stocks sol barer  chairman  president  centrexion  crunchbase httpswwwcrunchbasecompersonsolbarer dr barer is a biotechnology industry veteran and the founder and former chairman president coo and ceo of celgene a nasdaqlisted company nasd celg he brings  we found sol barer  beenverifiedcom ad · wwwbeenverifiedcom  sol barers phone  address  age  social profiles people search search by name search by email best background check social media get contact information sol barers history  sol barers past available online ad · recordstruthfindercom sol barers past available online simply search a name and state search records now best background check find out the truth learn more best people search search arrest records searches related tosol barer sol barer net worth sol barer biography sol barer worth sol barer mendham nj dr sol j barer sj barer consulting celgene immediate past chair next answers edge therapeutics chief accounting and operations bert marchio board of directors president  ceo co brian leuthner cso co r loch macdonald md phd board more erez vigodman role as cfo in february  teva announced that vigodman was stepping down as ceo with immediate effect and would be replace on an interim basis by more david cook album chris cornellbrian howespenned light on elsewhere cook exercises his right to rawk with the swaggering gritty barbasol and bares his soul more search the web  aol inc all rights reservedprivacy   terms of use   about our ads   preferences   contact us   powered by bing™ part of the aol search network